Key Players
Competitive Landscape
An oral nutrition product earns sustained use when its composition and administration fit the patient’s clinical plan. In intestinal failure, hydration, bowel anatomy and tolerance can change the appropriate choice. A broad formula catalog cannot substitute for specialist selection and monitoring.
Kate Farms’ flavored peptide introduction in 2025 adds an oral-use option, while Danone’s majority acquisition broadens the commercial platform behind the business. Continuity into home use depends on tolerability, palatability and reliable access, with parenteral support managed separately where still required.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| Kate Farms introduced Pediatric Peptide 1.0 strawberry in February 2025. | Long-duration nutrition use requires acceptable formats. | Medical nutrition lines add flavor options. | Support adherence where clinicians select the formula as appropriate. |
| Danone acquired a majority stake in Kate Farms in July 2025. | Specialized nutrition needs hospital and home access. | Medical nutrition businesses combine complementary portfolios. | Extend distribution and care-channel relationships. |
Format and distribution can improve access, but they do not establish suitability for every intestinal-failure patient or replace intravenous support when needed.
Source: Future Market Insights, Intestinal Failure Oral Nutrition Market, 2026 to 2036.
Elemental and peptide specialists compete on formula fit, while broader clinical nutrition businesses provide hospital relationships and continuity across care settings.
Why does oral suitability require separate assessment?
Patients differ in anatomy, absorption and hydration requirements. A formula marketed for gastrointestinal use is not automatically suitable for every form of intestinal failure.
What supports continuity after discharge?
An appropriate prescribed product, practical administration and dependable supply help patients and caregivers maintain the nutrition plan at home.
Representative Company Overview
| Company | Market-Relevant Capabilities |
|---|---|
| Danone Nutricia (Elemental 028) | Elemental oral nutrition products and specialist medical-nutrition channels. |
| Abbott | Peptide-based nutrition products such as Vital 1.5 Cal for appropriate clinical use. |
| Kate Farms | Plant-based peptide formulas with oral or tube-feeding options according to product indication. |
Research Methodology
Clinical company assessment distinguishes oral use from tube feeding and parenteral nutrition, considering composition, product indication, specialist access and home-supply continuity.
